Leverkusen, February 8, 2023

Effective June 1, 2023, William N. (Bill) Anderson will become the new Chairman of the Board of Management of Bayer AG. This was decided by the company’s Supervisory Board at its meeting today. Before assuming the position of Chairman of the Board, Bill Anderson will join the Board of Management of Bayer AG on April 1^st, 2023. The change of personnel in the position is the result of a diligent search and selection process that was kicked off mid last year.
Bill Anderson is a chemical engineer by education and has most recently served as CEO of Roche’s Pharmaceuticals Division. He will follow current CEO Werner Baumann, whose contract was originally scheduled to run until April 30, 2024. Werner Baumann will work closely with Bill Anderson to ensure a smooth transition process before retiring from Bayer end of May 2023.


Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


Contact:
Mr. Peter Dahlhoff, Bayer AG, Investor Relations, Tel.: +49 214 60001494 , e-mail: [email protected]